New Jersey is currently home to 1665 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 1 Study of Intratumoral Administration of VAX014 in Subjects with Advanced Solid Tumors
NCT05901285
Recruiting
The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for intratumoral injections (VAX014) in patients with advanced solid tumors. VAX014 is a targeted oncolytic agent designed to kill tumor cells following intratumoral injection into advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Atlantic Health System, Morristown, New Jersey
Conditions: Advanced Solid Tumor
Register for Updates
His-Bundle Corrective Pacing in Heart Failure
NCT05265520
Recruiting
The investigators aim to prospectively evaluate the efficacy and mechanism of benefit of His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) vs. cardiac resynchronization therapy (BIV-CRT) in patients with heart failure and right bundle branch block (RBBB).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Valley Health System, Paramus, New Jersey
Conditions: Right Bundle-Branch Block, Heart Failure, His-bundle Pacing, Cardiac Resynchronization Therapy
Register for Updates
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
NCT06801067
Recruiting
The purpose of this study is to find out whether SER-155 may be a safe first treatment that causes few or mild side effects for people due to irEC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Diarrhea, Enterocolitis
Register for Updates
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
NCT06698003
Recruiting
The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in some of their immune system cells called T-cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering at Basking Ridge (All protocol activities), Basking Ridge, New Jersey
Conditions: T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma, T-cell Leukemia, Lymphoma
Register for Updates
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391
Recruiting
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
03/03/2025
Locations: Cooper Health System, Camden, New Jersey
Conditions: Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes
Register for Updates
A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis
NCT06197685
Recruiting
The goal of this novel study is to compare the effect of a combined cognitive rehabilitation and exercise approach on new learning and memory (NLM) in persons with multiple sclerosis (pwMS) and mobility disability.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/03/2025
Locations: Kessler Foundation, East Hanover, New Jersey
Conditions: Multiple Sclerosis
Register for Updates
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
NCT06151197
Recruiting
This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Endo Site 62, Vineland, New Jersey
Conditions: Plantar Fibromatosis, Ledderhose Disease
Register for Updates
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
NCT05756777
Recruiting
The researchers are doing this study to see if the combination of gilteritinib with ivosidenib or enasidenib is a safe and effective treatment for people with relapsed/refractory AML with FLT3/IDH1 or FLT3/IDH2 gene mutations. The researchers will also look for the highest dose of the combination of gilteritinib with ivosidenib or enasidenib that causes few or mild side effects. When the highest safe dose is found, they will test that dose in new groups of participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Conditions: Acute Myeloid Leukemia (AML)
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: The Valley Hospital /ID# 243829, Paramus, New Jersey
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures
NCT04903314
Recruiting
The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
03/03/2025
Locations: Northeast Regional Epilepsy Group, Hackensack, New Jersey
Conditions: Partial Epilepsy
Register for Updates
Novel Imaging Technique to Assess Gynecologic Cancer
NCT04893434
Recruiting
This study will test a new type of DCE (dynamic contrast-enhanced) MRI (magnetic resonance imaging) to see whether, compared with traditional MRI, it produces better images that provide more information about tumors, which may help doctors make better decisions about treating women who have gynecologic cancer. MRI is commonly used to detect and evaluate many types of cancer, but its slow processing speed and the risk that images will be blurred if the patient moves inside the scanner can limit... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey
Conditions: Gynecologic Cancer
Register for Updates
Study of LAM561 Acid in Pediatric Patients with Malignant Glioma and Other Advanced Solid Tumors
NCT04299191
Recruiting
An open label, non-randomized study in pediatric patients with advanced high-grade gliomas and other solid tumors. The study will be performed in two phases: a dose escalation phase in up to 18 patients following a standard "3+3" design to establish dose-limiting toxicity (DLT) and a "safe" dose of LAM561 followed by an expanded safety cohort of up to 10 patients treated at the Maximum Tolerated Dose (MTD). If the MTD is well tolerated in the expanded safety cohort, that dose becomes the Recomm... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/03/2025
Locations: Hackensack Meridian Health, Inc, Edison, New Jersey
Conditions: High-grade Glioma, Solid Tumor, Unspecified, Child
Register for Updates